Sijmen de Vries, Pharming CEO

For­mer No­var­tis drug for ul­tra-rare dis­ease gets speedy FDA re­view

Three years af­ter pay­ing a mod­est $20 mil­lion up­front to grab a late-stage rare dis­ease drug from No­var­tis, Pharm­ing has lined up a pri­or­i­ty re­view …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.